Hellmann MD , Rizvi NA , Goldman JW , Gettinger SN , Borghaei H, Brahmer JR , et al. Nivolumab plus ipilimumab as first -line treatment for advanced non -small -cell lung cancer (CheckMate 012): results o f an open -label, phase 1, multicohort study. Lancet Oncol.